Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

Peer Review reports

Original Submission
26 Oct 2020	Submitted	Original manuscript
30 Oct 2020	Reviewed	Reviewer Report - Parth Mehta
3 Nov 2020	Reviewed	Reviewer Report - John Vaughn
6 Nov 2020	Author responded	Author comments - Deepu Madduri
Resubmission - Version 2
6 Nov 2020	Submitted	Manuscript version 2
9 Nov 2020	Reviewed	Reviewer Report - John Vaughn
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
23 Nov 2020	Editorially accepted
19 Feb 2021	Article published	10.1186/s13256-020-02598-0

Back to article page